August 27, 2014 6:43 PM ET

Healthcare Providers and Services

Company Overview of Dana-Farber Cancer Institute, Inc.

Company Overview

Dana-Farber Cancer Institute, Inc. provides cancer treatment and research services for adults and children in the United States. It offers adult treatment and care services for blood, breast, cutaneous/skin, gastrointestinal, genitourinary, gynecological, head and neck, hematology, melanoma, neuro-oncology, sarcoma, and thoracic cancer; and cancer genetics and prevention services. The company also provides treatment and care for children with cancer, such as blood diseases, bone and soft tissue tumors, brain tumors, histiocytosis, Hodgkin lymphoma, kidney tumors, leukemia, neuroblastoma, non-Hodgkin lymphoma, and rare tumors program. In addition, it offers training in cancer treatment and re...

450 Brookline Avenue

Boston, MA 02215-5450

United States

Founded in 1947

Phone:

617-632-3000

Fax:

617-632-3057

Key Executives for Dana-Farber Cancer Institute, Inc.

Chief Executive Officer and President
Chief Financial Officer and Assistant Treasurer
Chief Operating Officer and Executive Vice President
Age: 63
Senior Vice President and General Counsel
Senior Vice President for Research
Compensation as of Fiscal Year 2014.

Dana-Farber Cancer Institute, Inc. Key Developments

Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute's Belfer Institute for Applied Cancer Science

Johnson & Johnson Innovation announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline. Utilizing the Belfer Institute's proprietary immuno-oncology lung platform and lung cancer disease expertise, the research teams will also seek to identify rational immuno-oncology drug combination strategies and biomarkers, and to characterize mechanisms of resistance. The collaboration will also identify and validate novel targets for lung cancers. Lung cancer is one of three focus areas for Janssen Oncology based on its high unmet need.

Dana-Farber Cancer Institute, Inc. Presents at 7th Annual State of the Market Conference, Jun-19-2014 10:45 AM

Dana-Farber Cancer Institute, Inc. Presents at 7th Annual State of the Market Conference, Jun-19-2014 10:45 AM. Venue: The Plaza Hotel, New Y ork, New York, United States. Speakers: Edward J. Benz, Chief Executive Officer and President.

TrovaGene, Inc. Announces Clinical Collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations. A Dana-Farber oncology team, led by Jason Luke, M.D., will conduct clinical studies designed to monitor oncogene mutations in study subjects based on urinary cell-free DNA as an analytical specimen. Studies will be designed to collect data regarding the clinical status of patients, treatment effect, and long-term outcomes of therapy using Trovagene's non-invasive molecular diagnostic technology. Trovagene is engaged in numerous collaborations designed to demonstrate the clinical utility of its precision cancer monitoring platform for the detection of mutational status in cancer patients, and the assessment of tumor dynamics and treatment response over time. To date, the company has processed over 1,000 patient samples under its collaborations, and is focused on developing the clinical evidence to support broad market adoption of its technology.

Similar Private Companies By Industry

Company Name Region
SUN Behavioral Health United States
Northeastern Pennsylvania Imaging Center United States
Pacific Health Systems, LP United States
Cashmere Convalescent Center Inc. United States
Concordia Healthcare USA, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dana-Farber Cancer Institute, Inc., please visit www.dana-farber.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.